arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

KIORA PHARMACEUTICALS INC

KPRX
$2.80 ▲ +0.12 (+4.48%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

KIORA PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $17.3M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -13.1%
FCF / Share $-0.31
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-2.08M
↑ +3.4%
Operating Margin Operating profit as % of sales
82.6%
↑ +167.9%
FCF / Share Free cash flow per share
$-0.31
↑ +59.1%
Long-Term Debt Long-term obligations
$278.19K
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 51 quarters